Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biovie Inc (BIVI)

Biovie Inc (BIVI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 170,041
  • Shares Outstanding, K 61,166
  • Annual Sales, $ 0 K
  • Annual Income, $ -50,260 K
  • 60-Month Beta 0.74
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.89
Trade BIVI with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 174.13%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,006.04% on 04/17/24
  • IV Low 0.00% on 08/28/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 2
  • Volume Avg (30-Day) 49
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 3,245
  • Open Int (30-Day) 3,500

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.30
  • Growth Rate Est. (year over year) +43,534.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.07 +34.29%
on 08/06/24
4.05 -31.36%
on 08/01/24
-1.06 (-27.62%)
since 07/30/24
3-Month
2.07 +34.29%
on 08/06/24
5.00 -44.38%
on 06/12/24
-1.62 (-36.82%)
since 05/30/24
52-Week
2.07 +34.29%
on 08/06/24
58.20 -95.22%
on 11/22/23
-30.32 (-91.60%)
since 08/29/23

Most Recent Stories

More News
Why Shares of BioVie Jumped This Week

BioVie's announcement regarding a phase 2 trial for its lead therapy helped raise the stock's price.

BIVI : 2.78 (+0.36%)
Why Shares of BioVie Jumped 51.7% in February

The company is forging ahead with a phase 3 trial for its lead therapy.

BIVI : 2.78 (+0.36%)
Why Shares of BioVie Rose 15.3% in December

The biotech announced positive news from a pair of phase 2 clinical trials.

BIVI : 2.78 (+0.36%)
Why BioVie Stock Is Soaring Today

The more investors learned about BioVie's latest clinical results, the more they liked.

BIVI : 2.78 (+0.36%)
Why BioVie's Shares Tumbled Tuesday

The clinical-stage biotech released data on its prospective Alzheimer's therapy.

BIVI : 2.78 (+0.36%)
Pre-Market Brief: Stocks Mixed As Resurgent Fed Fears Weigh On Sentiment, China Reopening Hopes

December S&P 500 futures (ESZ22) are trending up +0.08% this morning after three major US benchmark indices finished the regular session sharply lower as market participants fretted that stronger-than-anticipated...

ESZ22 : 3,871.47s (-0.66%)
TSLA : 214.11 (+3.80%)
GTLB : 47.40 (-1.02%)
BIVI : 2.78 (+0.36%)
SUMO : 12.04 (-0.08%)
GIII : 26.47 (+0.61%)
AXON : 364.97 (+0.82%)
POWL : 167.44 (+2.85%)
BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201

CARSON CITY, Nev., June 23, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative...

BIVI : 2.78 (+0.36%)
BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

CARSON CITY, Nev., March 10, 2022 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), a clinical-stage company developing innovative drug therapies for the...

BIVI : 2.78 (+0.36%)
BioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference

RENO, Nev., March 09, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative...

BIVI : 2.78 (+0.36%)
BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease

RENO, Nev., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug...

BIVI : 2.78 (+0.36%)

Business Summary

BioVie Inc. engages in developing drug therapies for liver disease. The company's product candidate includes BIV201, which are in clinical stage. BioVie Inc. is based in SANTA MONICA, CA.

See More

Key Turning Points

3rd Resistance Point 2.96
2nd Resistance Point 2.90
1st Resistance Point 2.84
Last Price 2.78
1st Support Level 2.72
2nd Support Level 2.66
3rd Support Level 2.60

See More

52-Week High 58.20
Fibonacci 61.8% 36.76
Fibonacci 50% 30.14
Fibonacci 38.2% 23.51
Last Price 2.78
52-Week Low 2.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar